|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 May 2005, Vol. 105, No. 10, pp. 3841-3847. Prepublished online as a Blood First Edition Paper on January 27, 2005; DOI 10.1182/blood-2004-09-3708.
HEMATOPOIESIS
CCAAT/enhancer binding protein
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and methodsResultsDiscussionReferences |
|---|
, a member of the CCAAT/enhancer binding protein family, is a transcription factor important in neutrophil differentiation. We have determined that it is phosphorylated on multiple serine and threonine residues and can be a target for phosphorylation by a number of kinases. We identified a threonine at amino acid 75, part of a consensus mitogen-activated protein (MAP) kinase site within the transactivation domain of C/EBP, as being phosphorylated only by p38 MAP kinase. Phosphorylation of this residue resulted in enhanced transcriptional activity on a myeloid-specific promoter in in vitro transient transfection reporter assays. We also determined that phosphorylation at Thr75 yielded a protein that was more effective at binding its cognate DNA sequence compared with the wild-type nonphosphorylated C/EBP. Stable expression of C/EBPT75A in interleukin 3 (IL-3)–dependent 32Dcl3 did not result in the up-regulation of expression of secondary granule genes compared with wild-type C/EBP or C/EBPT75D. Therefore we suggest that C/EBP is a target for p38 MAP kinase activity. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
Many studies on transcription factors have demonstrated them to be modular proteins with separate domains for DNA binding and either transactivation or repression. C/EBP is a member of the CCAAT/enhancer binding protein family of transcription factors, which we previously demonstrated had both transactivation and repression domains.1,2 The CCAAT/enhancer binding protein family also includes C/EBP
, C/EBP
, C/EBP
, and CHOP/GADD153 (C/EBP homology protein/growth arrest and DNA damage-inducible gene 153).3-6 The members of the C/EBP family of transcription factors are phosphoproteins and the phosphorylation of these proteins has been shown to affect their function. C/EBP is the most extensively studied member of this transcription factor family with respect to phosphorylation.
C/EBP is phosphorylated by a number of protein kinases including protein kinase A (PKA), protein kinase C (PKC), glycogen synthase kinase 3 (GSK3), mitogen-activated protein kinases (MAPKs), ribosomal S6 kinase, and calcium-calmodulin kinase II (CaMKII). Phosphorylation affects a number of the functions of C/EBP, including inhibition of DNA binding, intracellular relocalization to the nucleus, increased transcriptional activity, and inhibition of apoptosis.7-12
C/EBP is a target for phosphorylation by PKC and GSK3.13,14 Although phosphorylation by PKC resulted in a decrease in DNA binding by C/EBP, phosphorylation by GSK3 did not appear to have any effect on C/EBP function.
In contrast to C/EBP and C/EBP, phosphorylation in the DNA binding domain of C/EBP by casein kinase 2 actually increased DNA binding.15 C/EBP can also be phosphorylated by MAPKs resulting in the translocation of this protein to the nucleus.16 MAP kinases can phosphorylate another member of the C/EBP family, CHOP/GADD153. In this case CHOP/GADD153 showed increased transcriptional activity.
Members of the C/EBP family are expressed in myeloid cells but appear to play different roles in differentiating and mature cells. C/EBP is expressed almost exclusively in myeloid cells with its expression reaching a peak in mature neutrophils and macrophages.17,18 Both C/EBP and C/EBP are regulators of cytokine gene expression in macrophages, whereas C/EBP is critical for granulocytic differentiation.19-21 As well as being expressed in hematopoietic cells, C/EBP, C/EBP, and CHOP/GADD153 also play an important role in adipocyte differentiation. The p38 MAP kinase can phosphorylate both C/EBP and CHOP/GADD153 with opposing effects on adipocyte differentiation. Phosphorylation of C/EBP by p38 MAPK is essential for adipocyte differentiation, whereas phosphorylation of CHOP/GADD153 by p38 MAPK results in an inhibition of adipocyte differentiation.22,23 Thus phosphorylation of transcription factors involved in the same pathway by the same kinase allows for tight regulation of that differentiation pathway. Also, phosphorylation of a specific transcription factor by a specific kinase may be required for the differentiation of a specific cell type.
Therefore, we studied C/EBP in order to determine the sites of phosphorylation, the kinases responsible for these phosphorylations, and the effect, if any, on C/EBP function. This study demonstrates that C/EBP is phosphorylated on multiple serine and threonine residues by a number of different kinases. We identified a phosphoacceptor site within the N-terminal transactivation domain of C/EBP that was specifically phosphorylated by p38 MAP kinase. Phosphorylation of this residue results in increased transactivation on a myeloid-specific promoter accompanied by increased binding of C/EBP to its cognate DNA sequence. C/EBP phosphorylated on this residue was also able to up-regulate the expression of myeloid-specific secondary granule genes in vivo.
|
Materials and methods |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
constructs
Single point mutations were introduced into wild-type C/EBP by polymerase chain reaction (PCR) using overlapping mutated oligonucleotides, followed by a second round of PCR using external primers containing appropriate restriction sites.24 The resulting PCR products were digested with the appropriate restriction enzymes and ligated into a cytomegalovirus (CMV)–expression vector, pCMV-SPORT (Invitrogen, Carlsbad, CA). The presence of these point mutations within C/EBP was confirmed by sequencing.
Transient transfections and reporter assays
Transient transfection assays were performed in Jurkat cells using lipofectin (Invitrogen) with 3 µg promoter-luciferase reporter and 0.3 µg of the C/EBP expression vectors, wild-type or mutants, as previously described.25 The internal control for transfection efficiency was 1 µg pCMV–-galactosidase. At 24 hours after transfection, the Jurkat cells were activated with TPA (12-O-tetradecanoyl phorbol 13-acetate; 2 ng/mL) and the calcium ionophore A23187
[GenBank]
(250 ng/mL) for 16 hours. After this time the transfections were harvested and the luciferase and -galactosidase activities were measured according to the manufacturer's instructions (Promega, Madison, WI). In some assays the following inhibitors (Calbiochem, San Diego, CA) were added for 60 minutes prior to activation: SB203580 (5 µM) and SB202190 (2.5 µM) for inhibition of p38 MAP kinase; H-89 (50 nM), an inhibitor of PKA; and KN-62 (1.5 µM), an inhibitor of CaMKII.
GST-C/EBP fusion proteins
C/EBP, C/EBPT75A, and C/EBPT75D were subcloned into pGEX-5X-1 and the resulting constructs transformed into BL-21 cells. The glutathione-S–transferase (GST)–C/EBP fusion proteins were isolated according to the manufacturer's instructions (Amersham-Pharmacia, Piscataway, NJ), with specific modifications. Following overnight growth, the culture was divided 1:10 and then grown for a further 60 minutes. The GST-C/EBP fusion protein was induced by 1 mM IPTG (isopropyl-B-D glucopyranoside) for 4 hours. The GST fusion proteins were then isolated by sonication and stored bound to the glutathione-sepharose beads in 50% glycerol. Expression of the GST fusion proteins was monitored by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western immunoblotting with a specific C/EBP antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
In vitro kinase assays
Equal amounts (5 µg) of the GST-C/EBP fusion proteins were incubated with the activated kinase (1-10 U) in kinase-specific reaction buffer containing 10 µCi (0.37 MBq) 
-32P–adenosine triphosphate. The kinases used for these assays were PKA (Roche, Indianapolis, IN), PKC (Roche), extracellular signal-related kinase 2 (ERK2; UBI, Lake Placid, NY), p38 MAP kinase (UBI), c-Jun N-terminal kinase (JNK2; UBI), casein kinase 2 (Roche), and CaMKII (UBI). The kinase reactions were incubated in appropriate kinase buffer at 30°C for 10 to 30 minutes and then stopped by the addition of Laemmli sample buffer (BioRad, Hercules, CA). The reactions were boiled and separated by SDS-PAGE. The gels were either dried for further analysis as described in the next section or the 32P-labeled protein was transferred to polyvinylidene fluoride (PVDF) membrane (Millipore, Bedford, MA) for immunoblotting with a C/EBP-specific antibody. 32P-labeled protein was detected by autoradiography.
Two-dimensional (2D) phospho–amino acid analysis
The in vitro–kinased GST-C/EBP fusion proteins were eluted overnight from the dried polyacrylamide gel in buffer P (25 mM N-ethylmorpholine, pH 7.7) and then precipitated. For 2D phospho–amino acid analysis the precipitated protein was treated with 6 M HCl for 60 minutes at 100°C and then lyophilized. The pellet was washed thoroughly and finally resuspended in pH 1.9 buffer (formic acid–acetic acid–water ratio, 1:3.1:35.9) and the liberated phospho–amino acids were separated on 100 µM thin-layer chromatography (TLC) plates (CBS Scientific, Del Mar, CA) on the Hunter thin layer peptide mapping electrophoresis system (HTLE-7000; CBS Scientific), with 1 µg cold phospho–amino acid standards. For 2D separation, the first dimension is electrophoresis in pH 1.9 buffer (formic acid–acetic acid–water ratio, 1:3.1:35.9) at 1.5 kV for 20 minutes and the second dimension is electrophoresis in pH 3.5 buffer (acetic acid–pyridine–water ratio, 10:1:189) at 1.3 kV for 16 minutes. Unlabeled phospho–amino acids were detected by ninhydrin staining of the TLC plate and the 32P-labeled phospho–amino acids were visualized by autoradiography.
Nuclear protein analysis
Jurkat cells were transfected with 5 µg of the CMV-C/EBP expression plasmids, wild-type and mutated, as described above. The empty vector pCMV-SPORT was used as the negative control for these experiments. Nuclear proteins were prepared as previously described.25 The nuclear extracts were initially separated by SDS-PAGE and analyzed by Western immunoblot to confirm expression of the various C/EBP proteins. DNA binding by the C/EBP proteins was determined by electrophoretic mobility shift assay (EMSA) using double-stranded oligonucleotides containing the C/EBP consensus site and adjacent sequences of the mim promoter.25 A standard reaction for the EMSA contained 2.5 ng 32P-labeled oligonucleotide, 10 µg Jurkat nuclear extract expressing either wild-type or mutated C/EBP, 1.5 µg poly dIdC (poly-deoxyinosinic-deoxycytidylic acid), and 4.5 µg bovine serum albumin in a 20-µL volume. Competing cold oligonucleotides at 100-fold molar excess or antibodies (1 µg) were added where indicated. Electrophoresis was performed on a 4% polyacrylamide gel at 34 mA for 2 to 3 hours. The gel was dried and the results visualized by autoradiography.
Transduction of C/EBP
The 32Dcl3 cells were cultured in Iscoves modified Dulbecco medium containing 10% fetal calf serum and 10% Wehi-3–conditioned medium. C/EBP, C/EBPT75A, C/EBPT75D, C/EBPS181D, and C/EBPS188D were ligated into the pBabePuro retroviral vector to allow for retroviral infection of 32Dcl3 cells. Bosc23 packaging cells were transfected with 5 µg of the pBabePuro-C/EBP constructs using GenePorter (GTS, San Diego, CA) as recommended by the manufacturer's instructions. At 48 hours after transfection, 32Dcl3 cells were infected by incubation with medium removed from the Bosc23 cells for 48 hours in the presence of 4 µg/mL polybrene.23 After this time the 32Dcl3 cells were transferred to medium containing 2 µg/mL puromycin. Puromycin-resistant 32D-C/EBP cells were expanded, and the expression of the wild-type and mutant C/EBP proteins was examined by Western immunoblotting with an antibody specific for C/EBP.
In order to demonstrate changes in 32Dcl3 cells occurring with the stable expression of C/EBP proteins, total RNA was isolated from exponentially growing 32D-C/EBP–expressing cells using Trizol according to the manufacturer's instructions (Invitrogen). Ten micrograms total RNA was separated on formaldehyde-agarose gels. The RNA was Northern blotted onto Hybond+ membrane with 10 x standard saline citrate (SSC), baked, and hybridized sequentially with 32P-–dCTP (32P-–deoxycytosine triphosphosphate)–labeled probes for the secondary granule genes NGAL and B9 and a probe for 18S as the control for equal sample loading of the gel.26 Results were visualized by autoradiography.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
can be phosphorylated in vitro by multiple kinases
Since other C/EBP family members have been shown to be the target of a number of kinases, we analyzed the protein sequence of C/EBP and identified a number of potential phosphoacceptor sites. We then carried out a series of in vitro kinase assays to confirm that C/EBP was a substrate for these kinases as suggested by the protein sequence. In vitro kinase assays demonstrated that GST-C/EBP could be phosphorylated by ERK2, p38 MAP kinase, and PKA (Figure 1A-C) but was not phosphorylated in vitro by JNK2, casein kinase 2, or PKC (Figure 1D-E; data not shown). CaMKII phosphorylated C/EBP weakly compared with the other kinases (Figure 1F). The appropriate positive controls were included in these kinase assays as verification of the activity of the kinase, and GST alone was not phosphorylated in any of these assays (Figure 1; data not shown).
Previously we had determined, by in vivo labeling, that C/EBP was phosphorylated on multiple serine and threonine residues but not on tyrosine residues.2 Furthermore, in vivo labeling with a series of previously described1 C/EBP deletion mutants demonstrated that only threonine residues were phosphorylated within the N-terminal transactivation domain of C/EBP (data not shown). Potentially both serine and threonine residues in C/EBP could be phosphorylated by PKA, ERK2, and p38 MAP kinase. Therefore we performed 2D phospho–amino acid analysis on the in vitro–kinased GST-C/EBP to determine the identity of the residues phosphorylated by each of these 3 kinases. This experiment demonstrated that both ERK2 and PKA kinase activity resulted in the phosphorylation of serine residues only (Figure 2A-B). However, phosphorylation of both threonine and serine residues was observed when GST-C/EBP was in vitro kinased by p38 MAP kinase (Figure 2C).
|
|
, 4 potential MAP kinase phosphoacceptor sites occur, 1 threonine and 3 serine residues. The serine residues are at amino acids 109, 181, and 188 and are all minimal MAP kinase sites (SP). The threonine residue is at amino acid 75 and is part of a consensus MAP kinase site (PGTP) within the N-terminal transactivation domain of C/EBP. Since this is the only potential site within C/EBP for the threonine phosphorylation observed with p38 MAP kinase, we mutated this residue to the nonphosphorylatable alanine GST-C/EBPT75A. This mutated GST-C/EBP was then used as a substrate in an in vitro kinase assay with p38 MAP kinase. The 2D phospho–amino acid analysis of the kinased GST-C/EBP confirmed that the mutation Thr75Ala did result in the loss of the threonine phosphorylation observed for the wild-type GST-C/EBP and p38 MAP kinase (Figure 2D). Therefore, these results suggest that Thr75 within the N-terminal transactivation domain of C/EBP is a target for the p38 MAP kinase signaling pathway.
Mutation of Thr75 alters the capacity of C/EBP to activate gene transcription
Although Thr75 appears to be a target for p38 MAP kinase in vitro, this does not necessarily mean that phosphorylation or lack of it at this site will affect the function of C/EBP in vivo. Studies of other C/EBP family members showed that some residues can be phosphorylated in vitro but not in vivo and vice versa.9,11 Therefore we wanted to determine whether mutation of this amino acid could affect the ability of C/EBP to transcriptionally activate a myeloid-specific promoter. Thus 2 C/EBP mutants, C/EBPT75A (nonphosphorylated) and C/EBPT75D (threonine to aspartate to mimic a phosphorylation event), were generated and subcloned into a CMV-driven expression vector. These 2 constructs were then used in transient transfection assays with a myeloid-specific promoter-luciferase construct and compared with the wild-type C/EBP activity on this promoter. The Jurkat cell line was used for these transient reporter assays since it does not express detectable levels of endogenous C/EBP.
In the transient reporter assays, the wild-type C/EBP activated the promoter-luciferase reporter construct by 7.5-fold, whereas the C/EBPT75A mutant activated the promoter only 3.7-fold (Figure 3). In contrast, C/EBPT75D was even more effective at activating the promoter, giving a 10.5-fold increase in activity on the promoter-luciferase reporter (Figure 3). These results suggest that phosphorylation (or lack of it) at Thr75 does have an effect on the ability of C/EBP to activate gene transcription. Furthermore, when a series of protein kinase inhibitors was used in these transient reporter assays, only inhibitors of p38 MAP kinase inhibited the ability of wild-type C/EBP to transactivate the promoter-luciferase reporter (Figure 3).
Mutation of minimal MAP kinase sites can also affect C/EBP function
We were also interested to examine the effect of phosphorylation on the 3 minimal MAP kinase sites; however, only 2 are conserved between human and murine C/EBP. These are Ser181 and Ser188, which are located in the C-terminal region of the repression domain of C/EBP. Therefore we generated mutations of these 2 serine residues converting each to either alanine or aspartate as we had done previously for Thr75. We then used these new constructs in transient transfection reporter assays using the mim promoter-luciferase construct.
For these 2 sites, C/EBPS181A and C/EBPS188D were able to activate the mim promoter-luciferase construct in these assays but were not as effective as the wild-type C/EBP (Figure 3). However, the other mutations C/EBPS181D and C/EBPS188A did not significantly activate the mim promoter (Figure 3).
Phosphorylation of other C/EBP family members has been shown to affect intracellular localization.8,27 Therefore, the expression of these mutant C/EBP proteins was examined (Figure 4). Western immunoblot analysis determined that all C/EBP proteins were expressed at similar levels but the C/EBPS188A mutant protein was the only one not localized to the nucleus (Figure 4). Subsequent analysis demonstrated that this mutant C/EBP protein appeared to now be localized to the cytoplasm, hence its lack of activity in the reporter assays (Figure 3).
|
|
Since all but 1 of our mutant C/EBP proteins are correctly localized to the nucleus and expressed at similar levels, we were interested to examine their ability to bind their cognate DNA sequence. Therefore gel shift analysis was performed using nuclear extracts from Jurkat cells transfected with either wild-type or mutant forms of C/EBP and an oligonucleotide from the mim promoter containing a cognate C/EBP binding site and surrounding sequences.
The gel shift analysis demonstrated that wild-type C/EBP, C/EBPT75A, C/EBPT75D, C/EBPS181A, C/EBPS181D, and C/EBPS188D all bound the oligonucleotide containing the C/EBP binding site from the mim promoter (Figure 5A). In these gel shift experiments, the DNA-protein complex could be competed away by the inclusion of the same unlabeled oligonucleotide and it could be supershifted with a C/EBP-specific antibody (Figure 5A).
Although all C/EBP proteins bound to the cognate DNA sequence, there appeared to be an increase DNA binding by the nuclear extract containing C/EBPT75D compared with the wild-type C/EBP (Figure 5A). Therefore we wanted to determine whether there was a real change in DNA binding by the C/EBPT75D mutant protein. Therefore, further EMSAs were carried out using a constant amount of the C/EBP proteins and increasing dilutions of the oligonucleotide (Figure 5B). Wild-type C/EBP demonstrated good binding for its cognate DNA sequence at 10 nM of oligonucleotide (Figure 5B). However, this DNA-protein complex was very weak even when the oligonucleotide was diluted to only 5 nM (Figure 5B). In contrast, binding of C/EBPT75D was strong even when the oligonucleotide had been diluted to 0.25 nM (Figure 5B). Scatchard analysis determined that the DNA binding affinity for wild-type C/EBP is 7.69 nM. This value is about the same as the DNA binding affinity of C/EBP previously determined by our group.25 In contrast, the DNA binding affinity of C/EBPT75D is 0.48 nM. This demonstrates that C/EBPT75D binds its cognate DNA with 16-fold more affinity than wild-type C/EBP. Therefore, phosphorylation of Thr75 dramatically increases the DNA binding ability of the C/EBP protein.
In vivo effects of C/EBPT75D expression
The previous experiments are all in vitro analyses for effects on C/EBP function after phosphorylation. Therefore we were interested in investigating the biologic effects of expression of phosphorylation mutants of C/EBP in a cell line capable of granulocytic differentiation. The 32Dcl3 cells were chosen for stable transfection. Following retroviral infection of the 32Dcl3 cells, a series of clones were isolated for each C/EBP protein. Protein lysates were made from each clone and analyzed by Western immunoblotting with an antibody specific for C/EBP. Clones were selected that expressed similar levels of the C/EBP proteins (Figure 6A).
|
knockout mice are deficient in secondary granule gene expression.27 Therefore we were interested to examine whether these stably transfected 32Dcl3 cells were expressing secondary granule genes, even when not undergoing differentiation. For this analysis RNA was isolated from exponentially growing 32Dcl3 cells, parental and stably transfected, and Northern blot analysis was carried out (Figure 6B). The results from this experiment demonstrate that constitutive expression of C/EBP in 32Dcl3 cells did affect endogenous secondary granule gene expression (Figure 6B). The secondary granule genes NGAL and B9 were both up-regulated in cells expressing wild-type C/EBP and C/EBPT75D (Figure 6B). However, more significantly, constitutive expression of C/EBPT75A did not result in the up-regulation of endogenous secondary granule gene expression (Figure 6B). This result demonstrates that phosphorylation of this threonine in the consensus MAP kinase site in C/EBP by p38 MAP kinase is important for the in vivo function of C/EBP.
Analysis of 32Dcl3 cells expressing either C/EBPS181D or C/EBPS188D demonstrated that neither of these mutant proteins could up-regulate secondary granule gene expression. This lack of activity correlated with their level of activity in the luciferase-reporter assays (Figure 3).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
is phosphorylated in vivo on multiple serine and threonine residues and that it is a substrate in vitro for the protein kinases PKA, ERK2, and p38 MAP kinase. The combination of these in vivo and in vitro analyses suggested that p38 MAP kinase was the protein kinase responsible for the phosphorylation of a threonine residue within the N-terminal transactivation domain of C/EBP.
Phosphorylation of this threonine residue resulted in an increase in the transactivation ability of C/EBP as determined by transient transfection reporter assays. EMSA analysis showed that this increase in activity on a myeloid-specific promoter was accompanied by an increase in the binding affinity of C/EBPT75D for its cognate DNA sequence compared with the wild-type C/EBP protein.
Transcription factors are generally organized into discrete domains responsible for the functions of DNA binding and transactivation. However, phosphorylation within 1 domain may affect the function of other separate domains within the whole protein. This effect might occur due to a change in conformation of the transcription factor as a result of phosphorylation. Studies on the transcription factors Ets-like gene-1 (Elk-1) and sphingolipid activator protein-1 (SAP-1) have suggested that their activity is regulated in this manner.28-30 For both of these transcription factors, phosphorylation of the C-terminal transactivation domain increased DNA binding via the N-terminal DNA binding domain. This suggests that the conformation change upon phosphorylation may unmask or alter the DNA binding surface of the transcription factor.
Therefore, we postulate that phosphorylation of C/EBP on Thr75 exerts such an effect on this transcription factor. It is possible that phosphorylation of Thr75 could change C/EBP from a "closed" conformation where it cannot bind DNA efficiently to a more "open" conformation allowing for much more efficient binding to its cognate DNA sequence.
|
function. The effect of phosphorylation on 2 serine residues within the repression domain of C/EBP was studied. For these, the effects were mixed and not as dramatic as for Thr75. Dephosphorylation of Ser188 appeared to relocalize the C/EBP protein to the cytoplasm. Whereas phosphorylation of Ser181 gave a C/EBP protein that could bind DNA as well as wild-type C/EBP but was inactive on a myeloid-specific promoter. We analyzed individually these 3 MAP kinase sites: Thr75, Ser181, and Ser188. However, in vivo distinct protein kinases and phosphatases exist that orchestrate the responses of a transcription factor to a variety of external stimuli. These transcription factors frequently contain both stimulatory and inhibitory phosphorylation sites, which allows for a dynamic process resulting in the fine tuning of the transactivation potential. Thus phosphorylation is a mechanism that provides for tight regulation of the activity of a transcription factor rather than being a simple switch for turning both on and off the activity of a transcription factor.
With respect to C/EBP, we suggest that Thr75 is frequently phosphorylated under normal growth conditions but that this is elevated upon other external stimuli. In this case, a stoichiometric shift occurs toward phospho-Thr75 in any given population of C/EBP molecules. Also, under these conditions the molar ratio between activating and repressing phosphorylation sites would determine the magnitude of transactivation function of C/EBP.
We next investigated the in vivo biologic effects of phosphorylation of C/EBP. The 32Dcl3 cells were stably transfected to constitutively express these C/EBP proteins, both wild-type and phosphorylation mutants. C/EBP plays a role in neutrophilic differentiation. Neutrophils are responsible for protecting the host against bacterial and fungal infections and are activated rapidly in response to inflammatory signals. In C/EBP knockout mice it was found that the cells of the granulocytic lineage have an impaired ability to migrate, a reduced capacity to produce superoxide, and do not express secondary granule proteins.27 The p38 MAP kinase is involved in mediating intracellular signals resulting in superoxide production and cell migration. In human neutrophils, inhibition of p38 MAP kinase results in decreased superoxide anion production, reduction in adhesion and chemotaxis in response to fMLP (formyl-methionyl-leucyl-phenylalanine), and inhibition of release of interleukin-8 (IL-8) in response to lipopolysaccharide (LPS).31,32 Therefore, p38 MAP kinase appears to be important for neutrophil function.
The defects observed for the C/EBP knockout mice are also observed in a number of diseases as well as other mouse knockout models. These include humans with specific granule disease, for which mutations of C/EBP have been identified, and chronic granulomatous disease, as well as Rac2 knockout mice.33-36 More recently a human neutrophil immunodeficiency syndrome has been identified resulting from a mutation of Rac2 (ras-related C3 botulinum toxin substrate 2).37 Rac2 is a member of the Rho family of guanosine triphosphatases (GTPases) that is highly expressed in myeloid cells and is a regulator of the nicotinamide adenine dinucleotide phosphate (NADPH)–oxidase complex. Therefore, the phenotype observed in C/EBP knockout mice represents a defect intrinsic to neutrophil function.
Neutrophils are rapidly activated and short-lived. Therefore, C/EBP has to be rapidly activated in response to an external stimulus. We hypothesize that C/EBP may be phosphorylated in nonstimulated neutrophils and bound to its cognate DNA sequence. Activation of p38 MAP kinase signaling pathways could then result in the rapid phosphorylation of the threonine residue at amino acid 75 such that C/EBP more efficiently binds DNA and can rapidly activate the transcription of genes necessary for neutrophil function.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Prepublished online as Blood First Edition Paper, January 27, 2005; DOI 10.1182/blood-2004-09-3708.
Supported by National Institutes of Health (NIH) grants (5 ROI CA26038-21 and 5 ROI CA26038-25), the Joseph Troy Fund, and the Parker Hughes Trust.
H.P.K. is a member of the Jonsson Comprehensive Cancer Center and the Molecular Biology Institute at UCLA.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Elizabeth A. Williamson, University of New Mexico, 1UNM/MSCO8 4630, Cancer Research Facility Room 117, Albuquerque, NM 87131; e-mail: ewilliamson{at}salud.unm.edu.
|
References |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
. J Biol Chem. 1998;273: 14796-14804. transcription factor. Mol Cell Biol. 1997;17: 1375-1386.[Abstract] (C/EBP). Biochem Biophys Res Comm. 1995;215: 106-113.[CrossRef][Medline]
[Order article via Infotrieve] (CRP3/CELF) gene: structure and chromosomal localization. Genomics. 1993;16: 520-523.[CrossRef][Medline]
[Order article via Infotrieve] phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. Mol Cell. 2001;8: 8807-8816.. J Biol Chem. 1997;272: 30356-30361. by modulating Akt and glycogen synthase kinase-3. J Biol Chem. 2001;276: 19664-19671.. Science. 1992;256: 370-373. kinase. Mol Cell Biol. 1999;19: 8433-8441.2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol. 1996;16: 1231-1240.[Abstract] directly interacts with the DNA binding domain of c-myb and cooperatively activates transcription of myeloid promoters. Blood. 1999;93: 3327-3337. and PU.1. Blood. 2003;101: 3265-3273.-deficient mice. Proc Natl Acad Sci U S A. 1997; 94: 13187-13192. mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. J Clin Invest. 1999; 103: 851-858.[Medline]
[Order article via Infotrieve]. Blood. 1999;93: 341-349.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Doulatov, F. Notta, K. L. Rice, L. Howell, A. Zelent, J. D. Licht, and J. E. Dick PLZF is a regulator of homeostatic and cytokine-induced myeloid development Genes & Dev., September 1, 2009; 23(17): 2076 - 2087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rizzi, M. P. Tschan, C. Britschgi, A. Britschgi, B. Hugli, T. J. Grob, N. Leupin, B. U. Mueller, H.-U. Simon, A. Ziemiecki, et al. The death-associated protein kinase 2 is up-regulated during normal myeloid differentiation and enhances neutrophil maturation in myeloid leukemic cells J. Leukoc. Biol., June 1, 2007; 81(6): 1599 - 1608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Gombart, J. Grewal, and H. P. Koeffler ATF4 differentially regulates transcriptional activation of myeloid-specific genes by C/EBP{epsilon} and C/EBP{alpha} J. Leukoc. Biol., June 1, 2007; 81(6): 1535 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Chumakov, A. Silla, E. A. Williamson, and H. P. Koeffler Modulation of DNA binding properties of CCAAT/enhancer binding protein epsilon by heterodimer formation and interactions with NFkappaB pathway Blood, May 15, 2007; 109(10): 4209 - 4219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lennartsson, K. Vidovic, M. B. Pass, J. B. Cowland, and U. Gullberg All-trans retinoic acid-induced expression of bactericidal/permeability-increasing protein (BPI) in human myeloid cells correlates to binding of C/EBP{beta} and C/EBP{epsilon} to the BPI promoter J. Leukoc. Biol., July 1, 2006; 80(1): 196 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Gombart, U. Krug, J. O'Kelly, E. An, V. Vegesna, and H. P. Koeffler Aberrant expression of neutrophil and macrophage-related genes in a murine model for human neutrophil-specific granule deficiency J. Leukoc. Biol., November 1, 2005; 78(5): 1153 - 1165. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
: changes in function upon phosphorylation by p38 MAP kinase
